Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Neuroimmunol ; 323: 73-77, 2018 10 15.
Artigo em Inglês | MEDLINE | ID: mdl-30196837

RESUMO

Adipokines secreted by fatty tissue have inflammatory properties and are suggested biomarkers of MS disease activity. To assess this, 88 MS patients were followed with nine repeated measurements of leptin and adiponectin and 12 magnetic resonance imaging (MRI) scans for two years; six months without any immunomodulatory treatment followed by 18 months during interferon-beta (IFNB) treatment. Serum levels of leptin dropped and adiponectin increased upon initiation of IFNB-therapy, but were not associated with clinical or MRI disease activity or with treatment response. Our findings indicate that leptin and adiponectin are not useful as biomarkers of MS disease activity.


Assuntos
Adiponectina/sangue , Progressão da Doença , Interferon beta/uso terapêutico , Leptina/sangue , Esclerose Múltipla/sangue , Esclerose Múltipla/tratamento farmacológico , Biomarcadores/sangue , Estudos de Coortes , Método Duplo-Cego , Feminino , Humanos , Fatores Imunológicos/uso terapêutico , Imageamento por Ressonância Magnética/tendências , Masculino , Esclerose Múltipla/diagnóstico por imagem , Estudos Prospectivos , Resultado do Tratamento
2.
BMC Neurol ; 16(1): 197, 2016 Oct 18.
Artigo em Inglês | MEDLINE | ID: mdl-27756254

RESUMO

BACKGROUND: Leber's hereditary optic neuropathy (LHON) co-occuring with multiple sclerosis-like disease (LHON-MS) is suggested to be a separate disease entity denoted Harding's disease. Little is known about the response to initiation and discontinuation of potent immunomodulatory treatment in LHON-MS. CASE PRESENTATION: We describe a LHON-MS patient with 27 years disease duration who developed severe disease activity peaking 14 months after discontinuation of natalizumab, with extensive new inflammatory lesions throughout the brain and in the spinal cord resembling immune inflammatory reconstitution syndrome. She had previously been clinically and radiologically stable on natalizumab treatment for 6 years, and before that only experienced subtle clinical activity during 9 years on interferon beta1a. CONCLUSION: This is the first report on severe exacerbation of inflammatory disease activity after discontinuation of natalizumab in LHON-MS, and suggests that late rebound activity can occur in these patients.


Assuntos
Inflamação/complicações , Esclerose Múltipla/complicações , Esclerose Múltipla/patologia , Natalizumab/administração & dosagem , Natalizumab/uso terapêutico , Atrofia Óptica Hereditária de Leber/complicações , Atrofia Óptica Hereditária de Leber/patologia , Recidiva , Adulto , Encéfalo/patologia , Feminino , Humanos , Inflamação/diagnóstico por imagem , Inflamação/patologia , Imageamento por Ressonância Magnética , Masculino , Esclerose Múltipla/diagnóstico por imagem , Esclerose Múltipla/tratamento farmacológico , Atrofia Óptica Hereditária de Leber/diagnóstico por imagem , Atrofia Óptica Hereditária de Leber/tratamento farmacológico , Medula Espinal/patologia , Fatores de Tempo
3.
Neurol Neuroimmunol Neuroinflamm ; 3(4): e260, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27458599

RESUMO

OBJECTIVE: To study whether tobacco use is associated with MRI and clinical disease activity in patients with multiple sclerosis (MS). METHODS: Prospective cohort study of 87 patients with relapsing-remitting MS originally included in a randomized placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS Study). Serum levels of cotinine (biomarker of tobacco use) were analyzed at baseline and every 6 months for 2 years. MRI activity was assessed at baseline and monthly for 9 months and after 12 and 24 months. RESULTS: Fifty-three patients (61%) had serum cotinine levels ≥85 nmol/L on ≥60% of the measurements and were considered tobacco users and 34 (39%) had cotinine levels <85 nmol/L, consistent with non-tobacco use. There was no association between tobacco use and the occurrence of new gadolinium-enhancing T1 lesions, new or enlarging T2 lesions, or their aggregate (combined unique activity). Furthermore, there was no association between cotinine levels and MRI activity for the tobacco users, and tobacco users did not have more relapses or Expanded Disability Status Scale progression. CONCLUSION: Our results indicate that tobacco use does not directly influence MRI activity or relapse rate in MS. This may implicate that the reported association between smoking and MS disease progression could be mediated through other mechanisms.

4.
J Neuroimmunol ; 288: 92-7, 2015 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-26531700

RESUMO

Obesity is a possible risk factor of multiple sclerosis (MS), but the association between obesity and MS disease activity has not been explored. In a cohort of 86 MS patients, 80% of overweight or obese patients (BMI≥25kg/m(2)) had MRI activity compared to 48% of the normal-weight patients (BMI<25kg/m(2)) (p=0.001) during interferon-beta treatment. NEDA-status (no evidence of disease activity) was defined as a composite that consisted of absence of any relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-status compared to only 13% of patients with BMI >25 (p=0.05). This may indicate that BMI affects interferon-beta treatment response.


Assuntos
Fatores Imunológicos/uso terapêutico , Interferon beta/uso terapêutico , Esclerose Múltipla Recidivante-Remitente/complicações , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Esclerose Múltipla Recidivante-Remitente/patologia , Obesidade/complicações , Adolescente , Adulto , Índice de Massa Corporal , Encéfalo/patologia , Progressão da Doença , Método Duplo-Cego , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Inflamação/etiologia , Inflamação/patologia , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Adulto Jovem
5.
J Neuroimmunol ; 280: 21-8, 2015 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-25773151

RESUMO

To explore if vitamin D modulates interferon-ß1a treatment effects in relapsing-remitting multiple sclerosis, we examined relationships between serum vitamin D and magnetic resonance imaging (MRI) activity and ten systemic inflammation markers in 88 patients, before and during treatment. Odds ratios for all MRI parameters were negatively associated with vitamin D levels before therapy, but converged to equally low values irrespective of vitamin D status during treatment. During therapy, similar alterations of MRI activity and inflammation markers were found across patients categorized by mean vitamin D values. This suggests that vitamin D status has no major influence on interferon-ß1a treatment effects.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Interferon beta/uso terapêutico , Imageamento por Ressonância Magnética , Esclerose Múltipla Recidivante-Remitente , Vitamina D/sangue , Adolescente , Adulto , Citocinas/sangue , Feminino , Humanos , Interferon beta-1a , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/sangue , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Esclerose Múltipla Recidivante-Remitente/patologia , Noruega , Análise de Regressão , Estudos Retrospectivos , Fatores de Tempo , Adulto Jovem
6.
Mult Scler ; 20(14): 1833-40, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24842958

RESUMO

BACKGROUND: Previous reports indicate an association between Epstein-Barr virus (EBV) antibody levels and multiple sclerosis (MS) disease activity, but the results have been conflicting. OBJECTIVES: The objective of this paper is to study if EBV antibody levels reflect MRI disease activity in MS and examine the potential for EBV antibody levels as biomarkers for treatment response. METHODS: A total of 87 MS patients were followed for two years prior to and during interferon beta (IFNB) treatment, with MRI examinations and serum measurement of IgM and IgG antibodies to viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA-1) and early antigen (EA). Associations between EBV antibody levels and MRI activity were assessed by a logistic regression model. RESULTS: Higher anti-EBNA-1 IgG levels were associated with increased MRI activity, OR = 2.95 (95% CI 1.07-8.10; p = 0.036) for combined unique activity (CUA; the sum of T1Gd+ lesions and new or enlarging T2 lesions). Although most patients were anti-VCA IgM negative, there was an inverse association, OR = 0.32 (95% CI 0.12-0.84; p = 0.021) with CUA during IFNB treatment. CONCLUSIONS: This study supports an association between anti-EBNA-1 IgG levels and MS disease activity. We also found an inverse association with anti-VCA IgM levels during IFNB treatment not previously described, indicating anti-VCA IgM as a possible biomarker for IFNB treatment response.


Assuntos
Anticorpos Antivirais/imunologia , Encéfalo/patologia , Herpesvirus Humano 4/imunologia , Esclerose Múltipla/imunologia , Adulto , Antígenos Virais/imunologia , Proteínas do Capsídeo/imunologia , Antígenos Nucleares do Vírus Epstein-Barr/imunologia , Ácidos Graxos Ômega-3/uso terapêutico , Feminino , Humanos , Imunoglobulina G/imunologia , Imunoglobulina M/imunologia , Fatores Imunológicos/uso terapêutico , Interferon beta-1a , Interferon beta/uso terapêutico , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/tratamento farmacológico , Esclerose Múltipla/patologia , Estudos Prospectivos , Índice de Gravidade de Doença
7.
J Neuroimmunol ; 271(1-2): 60-5, 2014 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-24713402

RESUMO

To explore the relationships between vitamin A, D and E and inflammation in relapsing remitting multiple sclerosis, we assessed their associations with 11 inflammation markers in 9 serial serum samples from 85 patients, before and during interferon-ß1a treatment. A negative association was found between vitamin A and pentraxin 3 independent of interferon-ß1a use, whereas positive associations between vitamin D and interleukin-1 receptor antagonist and secreted frizzled-related protein 3 were seen before, and between vitamin E and chemokine (C-X-C motif) ligand 16 during interferon-ß1a treatment. These findings suggest associations with diverse inflammatory pathways, which may be differentially influenced by interferon-ß1a treatment.


Assuntos
Citocinas/sangue , Esclerose Múltipla/sangue , Esclerose Múltipla/imunologia , Vitaminas/sangue , Adulto , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Ácidos Docosa-Hexaenoicos/uso terapêutico , Método Duplo-Cego , Ácido Eicosapentaenoico/uso terapêutico , Feminino , Seguimentos , Humanos , Fatores Imunológicos/uso terapêutico , Interferon beta/uso terapêutico , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/tratamento farmacológico , Componente Amiloide P Sérico/metabolismo , Fatores de Tempo , Vitamina A/sangue , Vitamina D/sangue , Vitamina E/sangue
8.
PLoS One ; 8(9): e75021, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24069377

RESUMO

BACKGROUND: Serum markers of inflammation are candidate biomarkers in multiple sclerosis (MS). ω-3 fatty acids are suggested to have anti-inflammatory properties that might be beneficial in MS. We aimed to explore the relationship between serum levels of inflammation markers and MRI activity in patients with relapsing remitting MS, as well as the effect of ω-3 fatty acids on these markers. METHODS: We performed a prospective cohort study in 85 relapsing remitting MS patients who participated in a randomized clinical trial of ω-3 fatty acids versus placebo (the OFAMS study). During a period of 24 months 12 repeated magnetic resonance imaging (MRI) scans and nine serum samples were obtained. We measured 10 inflammation markers, including general down-stream markers of inflammation, specific markers of up-stream inflammatory pathways, endothelial action, and matrix regulation. RESULTS: After Bonferroni correction, increasing serum levels of CXCL16 and osteoprotegerin were associated with low odds ratio for simultaneous MRI activity, whereas a positive association was observed for matrix metalloproteinase (MMP) 9. CXCL16 were also associated with low MRI activity the next month, but this was not significant after Bonferroni correction. In agreement with previously reported MRI and clinical results, ω-3 fatty acid treatment did not induce any change in the inflammation markers. CONCLUSIONS: Serum levels of CXCL16, MMP-9, and osteoprotegerin reflect disease activity in MS, but are not affected by ω-3 fatty acid treatment. CXCL16 could be a novel biomarker and potential predictor of disease activity in MS.


Assuntos
Quimiocinas CXC/sangue , Esclerose Múltipla/sangue , Esclerose Múltipla/diagnóstico , Receptores Depuradores/sangue , Biomarcadores/sangue , Quimiocina CXCL16 , Suplementos Nutricionais , Ácidos Graxos Ômega-3/uso terapêutico , Feminino , Humanos , Inflamação/sangue , Imageamento por Ressonância Magnética , Masculino , Esclerose Múltipla/dietoterapia , Razão de Chances , Prognóstico
9.
PLoS One ; 8(1): e54417, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23349882

RESUMO

OBJECTIVE: Alpha-tocopherol is the main vitamin E compound in humans, and has important antioxidative and immunomodulatory properties. The aim of this study was to study alpha-tocopherol concentrations and their relationship to disease activity in Norwegian multiple sclerosis (MS) patients. METHODS: Prospective cohort study in 88 relapsing-remitting MS (RRMS) patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids (the OFAMS study), before and during treatment with interferon beta. The patients were followed for two years with repeated 12 magnetic resonance imaging (MRI) scans and nine serum measurements of alpha-tocopherol. RESULTS: During interferon beta (IFNB) treatment, each 10 µmol/L increase in alpha-tocopherol reduced the odds (CI 95%) for simultaneous new T2 lesions by 36.8 (0.5-59.8) %, p = 0.048, and for combined unique activity by 35.4 (1.6-57.7) %, p = 0.042, in a hierarchical regression model. These associations were not significant prior to IFNB treatment, and were not noticeably changed by gender, age, body mass index, HLA-DRB1*15, treatment group, compliance, or the concentrations of 25-hydroxyvitamin D, retinol, neutralising antibodies against IFNB, or the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid. The corresponding odds for having new T1 gadolinium enhancing lesions two months later was reduced by 65.4 (16.5-85.7) %, p = 0.019, and for new T2 lesions by 61.0 (12.4-82.6) %, p = 0.023. CONCLUSION: During treatment with IFNB, increasing serum concentrations of alpha-tocopherol were associated with reduced odds for simultaneous and subsequent MRI disease activity in RRMS patients.


Assuntos
Interferon beta/efeitos adversos , Esclerose Múltipla Recidivante-Remitente/sangue , Esclerose Múltipla Recidivante-Remitente/fisiopatologia , alfa-Tocoferol/sangue , Adulto , Estudos de Coortes , Ácidos Graxos Ômega-3/metabolismo , Feminino , Seguimentos , Gadolínio , Cadeias HLA-DRB1 , Humanos , Interferon beta/administração & dosagem , Imageamento por Ressonância Magnética , Masculino , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Estudos Prospectivos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
10.
Mult Scler ; 19(4): 451-7, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22907941

RESUMO

BACKGROUND: Vitamin A has immunomodulatory properties and may regulate the transcription of genes involved in remyelination. OBJECTIVE: To investigate the association between retinol and disease activity in multiple sclerosis (MS). METHODS: Cohort study of 88 relapsing-remitting MS patients, originally included in a randomised placebo-controlled trial of omega-3 fatty acids in MS (the OFAMS study), followed prospectively for 24 months with repeated assessments of serum-retinol and magnetic resonance imaging (MRI). All patients were initiated on interferon ß-1a after month 6. RESULTS: Each 1 µmol/L increase in serum-retinol reduced the odds (95% confidence interval) for new T1 gadolinium enhanced (Gd(+)) lesions by 49 (8-70)%, new T2 lesions by 42 (2-66)%, and combined unique activity (CUA) by 46 (3-68)% in simultaneous MRI scans, and 63 (25-82)% for new T1Gd(+) lesions, 49 (3-73)% for new T2 lesions and 43 (12-71)% for CUA the subsequent month. Serum-retinol also predicted new T1Gd(+) and T2 lesions six months ahead. The associations were not affected by HLA-DRB1*15, or serum levels of 25-hydroxyvitamin D, eicosapentaenoic acid or docosahexaenoic acid. CONCLUSION: Serum retinol is inversely associated with simultaneous and subsequent MRI outcomes in RRMS.


Assuntos
Esclerose Múltipla Recidivante-Remitente/sangue , Esclerose Múltipla Recidivante-Remitente/patologia , Vitamina A/sangue , Adulto , Cromatografia Líquida de Alta Pressão , Ácidos Graxos Ômega-3/uso terapêutico , Feminino , Humanos , Fatores Imunológicos/uso terapêutico , Interferon beta/uso terapêutico , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Adulto Jovem
11.
Arch Neurol ; 69(8): 1044-51, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22507886

RESUMO

OBJECTIVE: To investigate whether ω-3 fatty acids reduce magnetic resonance imaging (MRI) and clinical disease activity in patients with multiple sclerosis, both as monotherapy and in combination with interferon beta-1a treatment. DESIGN: Multicenter, randomized, double-blind, placebo-controlled clinical trial conducted from 2004 to 2008. SETTING: Thirteen public neurology departments in Norway. PARTICIPANTS: Patients aged 18 to 55 years with active relapsing-remitting multiple sclerosis, with a disability score equivalent to 5.0 or less on the Kurtzke Expanded Disability Status Scale. Ninety-two patients were randomized to ω-3 fatty acids (n = 46) or placebo capsules (n = 46). INTERVENTIONS: Administration of 1350 mg of eicosapentaenoic acid and 850 mg of docosahexaenoic acid daily or placebo. After 6 months, all patients in addition received subcutaneously 44 µg of interferon beta-1a 3 times per week for another 18 months. MAIN OUTCOME MEASURE: The primary outcome measure was MRI disease activity as measured by the number of new T1-weighted gadolinium-enhancing lesions during the first 6 months. Secondary outcome measures included MRI disease activity after 9 months and 24 months, relapse rate, disability progression, fatigue, quality of life, and safety. RESULTS: The cumulative number of gadolinium-enhancing MRI lesions during the first 6 months were similar in the ω-3 fatty acids and placebo groups (median difference, 1; 95% CI, 0 to 3; P = .09). No difference in relapse rate was detected after 6 (median difference, 0; 95% CI, 0 to 0; P = .54) or 24 (median difference, 0; 95% CI, 0 to 0; P = .72) months. The proportion of patients without disability progression was 70% in both groups (P > .99). No differences were detected in fatigue or quality-of-life scores, and no safety concerns appeared. Serum analyses of fatty acids showed an increase in ω-3 fatty acids (mean difference, 7.60; 95% CI, 5.57 to 7.91; P < .001) in the patients treated with ω-3 fatty acids compared with the placebo group. CONCLUSION: No beneficial effects on disease activity were detected from ω-3 fatty acids when compared with placebo as monotherapy or in combination with interferon beta-1a. Magnetic resonance imaging disease activity was reduced as expected by interferon beta-1a. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00360906.


Assuntos
Ácidos Graxos Ômega-3/administração & dosagem , Esclerose Múltipla/tratamento farmacológico , Esclerose Múltipla/patologia , Adulto , Suplementos Nutricionais , Método Duplo-Cego , Quimioterapia Combinada , Feminino , Humanos , Interferon beta-1a , Interferon beta/administração & dosagem , Imageamento por Ressonância Magnética/tendências , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/epidemiologia , Resultado do Tratamento
12.
Tidsskr Nor Laegeforen ; 132(5): 523-6, 2012 Mar 06.
Artigo em Inglês, Norueguês | MEDLINE | ID: mdl-22398768

RESUMO

BACKGROUND: The motor and non-motor symptoms of multiple sclerosis often result in a substantially reduced health-related quality of life. We surveyed patient satisfaction and own evaluation of the benefit of a period spent at a specialised rehabilitation centre. MATERIAL AND METHOD: All patients who spent a period at the Hakadal MS rehabilitation centre in 2010 were asked to complete a validated questionnaire designed to determine patient satisfaction with rehabilitation institutions. RESULTS: Of a total of 339 patients, 277 (82%) returned the questionnaire. The great majority of respondents were satisfied with the knowledge, cooperation, care and engagement of those providing treatment, as well as with the advance information provided and the premises. They also found that they were consulted concerning their rehabilitation programme and that they were prepared for the period following their stay. More than 85% of the respondents stated that the stay would have major or very great importance for their general qualify of life and physical health. A similar score for mental health was given by 83%, mastery of day-to-day tasks by 77% and participation in social activities by 71%. INTERPRETATION: Patients who have had stays at the Hakadal MS rehabilitation centre are satisfied and feel that the stay will be of great importance to their level of functioning and mastery.


Assuntos
Esclerose Múltipla/reabilitação , Satisfação do Paciente , Atividades Cotidianas , Adulto , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Esclerose Múltipla/psicologia , Noruega , Avaliação de Programas e Projetos de Saúde , Qualidade de Vida , Centros de Reabilitação , Inquéritos e Questionários
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...